RecruitingNCT06665776

HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

A Prospective Observational Human Subject Research to Explore the HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

Sponsor

PharmaEssentia

Enrollment

1,200 participants

Start Date

Mar 14, 2023

Study Type

OBSERVATIONAL

Conditions

Solid Tumor Malignancy

Summary

This is a prospective observational research to explore the frequency of Human leukocyte antigen A allele 02:01 (HLA\*02:01) and the expression status of New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in cancer patients in Taiwanese population.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with solid tumor malignancy. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(6)

Chang Gung Memorial Hospital, Chiayi Branch

Chiayi City, Taiwan, Taiwan

Taichung Veterans General Hospital

Taichung, Taiwan, Taiwan

National Cheng Kung University Hospital

Tainan, Taiwan, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan, Taiwan

National Taiwan University Hospital

Taipei, Taiwan, Taiwan

Taipei Medical University Hospital

Taipei, Taiwan, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06665776

Related Trials

Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients

NCT069114892 locations

A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients

NCT069853681 location

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

NCT057682697 locations